245 related articles for article (PubMed ID: 10741731)
41. Comparison of mutational changes in involved N1 lymph nodes with those in primary tumors in stage II non-small cell lung cancer: a pilot study.
Fernando HC; Sasatomi E; Christie NA; Buenaventura PO; Finkelstein SD; Yousem SA; Soose R; Close JM; Luketich JD
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):87-91. PubMed ID: 14752417
[TBL] [Abstract][Full Text] [Related]
42. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.
Mitsudomi T; Hamajima N; Ogawa M; Takahashi T
Clin Cancer Res; 2000 Oct; 6(10):4055-63. PubMed ID: 11051256
[TBL] [Abstract][Full Text] [Related]
44. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
45. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
[TBL] [Abstract][Full Text] [Related]
46. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes.
Marchetti A; Buttitta F; Merlo G; Diella F; Pellegrini S; Pepe S; Macchiarini P; Chella A; Angeletti CA; Callahan R
Cancer Res; 1993 Jun; 53(12):2846-51. PubMed ID: 8389245
[TBL] [Abstract][Full Text] [Related]
47. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Kjaer SK; Blaakaer J; Christensen L; Glud E; Vuust J; Høgdall CK
Gynecol Oncol; 2006 Jan; 100(1):76-82. PubMed ID: 16183105
[TBL] [Abstract][Full Text] [Related]
48. TP53 mutation, allelism and survival in non-small cell lung cancer.
Nelson HH; Wilkojmen M; Marsit CJ; Kelsey KT
Carcinogenesis; 2005 Oct; 26(10):1770-3. PubMed ID: 15905205
[TBL] [Abstract][Full Text] [Related]
49. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
[TBL] [Abstract][Full Text] [Related]
50. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
[TBL] [Abstract][Full Text] [Related]
51. [Lung cancer in women: clinical features and factors related to survival].
Sen E; Kaya A; Erol S; Savas I; Gonullu U
Tuberk Toraks; 2008; 56(3):266-74. PubMed ID: 18932027
[TBL] [Abstract][Full Text] [Related]
52. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
53. Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status.
Ou SH; Zell JA; Ziogas A; Anton-Culver H
Cancer; 2008 May; 112(9):2011-20. PubMed ID: 18361399
[TBL] [Abstract][Full Text] [Related]
54. Evidence for common clonal origin of multifocal lung cancers.
Wang X; Wang M; MacLennan GT; Abdul-Karim FW; Eble JN; Jones TD; Olobatuyi F; Eisenberg R; Cummings OW; Zhang S; Lopez-Beltran A; Montironi R; Zheng S; Lin H; Davidson DD; Cheng L
J Natl Cancer Inst; 2009 Apr; 101(8):560-70. PubMed ID: 19351924
[TBL] [Abstract][Full Text] [Related]
55. p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up.
Russo A; Migliavacca M; Zanna I; Valerio MR; Latteri MA; Grassi N; Pantuso G; Salerno S; Dardanoni G; Albanese I; La Farina M; Tomasino RM; Gebbia N; Bazan V
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1322-31. PubMed ID: 12433709
[TBL] [Abstract][Full Text] [Related]
56. p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer.
Ryberg D; Kure E; Lystad S; Skaug V; Stangeland L; Mercy I; Børresen AL; Haugen A
Cancer Res; 1994 Mar; 54(6):1551-5. PubMed ID: 8137262
[TBL] [Abstract][Full Text] [Related]
57. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.
Bodner SM; Minna JD; Jensen SM; D'Amico D; Carbone D; Mitsudomi T; Fedorko J; Buchhagen DL; Nau MM; Gazdar AF
Oncogene; 1992 Apr; 7(4):743-9. PubMed ID: 1565469
[TBL] [Abstract][Full Text] [Related]
58. Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma.
van Slooten HJ; van De Vijver MJ; Borresen AL; Eyfjörd JE; Valgardsdóttir R; Scherneck S; Nesland JM; Devilee P; Cornelisse CJ; van Dierendonck JH
J Pathol; 1999 Dec; 189(4):504-13. PubMed ID: 10629550
[TBL] [Abstract][Full Text] [Related]
59. Gender differences in p53 mutational status in small cell lung cancer.
Tseng JE; Rodriguez M; Ro J; Liu D; Hong WK; Mao L
Cancer Res; 1999 Nov; 59(22):5666-70. PubMed ID: 10582680
[TBL] [Abstract][Full Text] [Related]
60. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
Lianidou ES; Levesque MA; Katsaros D; Angelopoulou K; Yu H; Genta F; Arisio R; Massobrio M; Bharaj B; Diamandis EP
Anticancer Res; 1999; 19(1B):749-56. PubMed ID: 10216487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
